Obesity care in the UK – why it can’t improve until it is recognised as a disease

For decades, obesity has been framed as a lifestyle issue, a consequence of eating too much and moving too little. And yet, research in metabolic physiology, neuroendocrinology and genetics has fundamentally changed our understanding of the condition. Body weight is regulated by complex biological systems – governed by the brain through appetite, hormonal signalling and energy expenditure – in ways that differ from person to person. Genetic variation in hormonal pathways involving leptin and ghrelin directly influences how individuals regulate appetite and weight.

The World Health Organization (WHO) formally classified obesity as a chronic disease over twenty years ago. The UK has not followed suit, and the result is a healthcare system that has struggled to operationalise obesity care with the same consistency it applies to other long-term conditions, leaving patients navigating fragmented, episodic support rather than the structured, long-term management we would consider standard for conditions such as diabetes or cardiovascular disease. Some will argue that recognition risks over-medicalising a lifestyle issue, but obesity is influenced by behaviour, not reducible to it. Recognising it as a disease does not exclude lifestyle intervention, it strengthens it by placing behavioural support within a clinical framework that acknowledges the biological drivers patients are working against.

Nearly two-thirds of adults in England (64.5%) are overweight or living with obesity, one of the highest rates in Western Europe. Those are not abstract figures, they represent millions of people managing a chronic condition without the clinical framework that should exist to support them.

That policy gap has consequences that extend beyond clinical infrastructure. Because obesity is not formally recognised as a disease, it continues to be perceived by society, and often by patients themselves, as a personal failing rather than a medical condition. Voy’s recent health index, Unembarrassing Bodies, a survey of over 15,000 British adults, found that only 8% believe weight stigma is a thing of the past. That stigma has a direct clinical consequence and many people never seek help at all, managing their weight privately and in isolation rather than engaging with healthcare services.

For those who do come forward, the delay is often significant. In my experience, patients arrive having already attempted numerous weight loss strategies independently, and when those attempts have not worked, which is common given the body’s metabolic adaptation mechanisms, they carry not just the physical burden of their condition but a history of perceived failure that shapes how they engage with treatment.

That same stigma distorts how patients measure progress if they do engage. Major trials including Look AHEAD, DiRECT and SELECT have reinforced that modest, sustained weight loss of just 5-10% delivers substantial health improvements and a reduction in long-term cardiometabolic risk, even if it falls short of patients’ targets. But without a disease framework that sets clinical goalposts, patients continue to measure success against social ideals and aesthetics rather than medical outcomes and feel they have failed even when the clinical evidence says otherwise.

Commercial content volume increases ~37% every year, making modular, reusable content blocks a practical necessity. Need an on-label Tweet thread or a patient brochure? AI can draft both from the same approved content, ensuring consistency while speeding up creation and review. Content hives built on approved medical knowledge and generative tools can suggest how to tailor modules for each audience. Instead of creating every asset anew, marketers build pre-approved content blocks that can be adapted for multiple channels.

There is a fundamental inconsistency in how obesity is managed compared with other diseases. In conditions such as hypertension or type 2 diabetes, long-term medication use for disease control and maintenance is widely accepted as part of ongoing care. 

In obesity, treatment is still predominantly focused on short-term intervention and initial weight loss, with far less emphasis on what happens once initial targets are reached. Some might argue this places too much responsibility on the medical system and not enough on the individual. But recognising obesity as a disease does not separate the condition from the patient. It reframes responsibility with a better understanding of the disease and supports patients to play an active role in managing their health within a system that can provide the appropriate clinical tools.

Weight loss triggers well-documented physiological adaptations, including increases in hunger hormones and reductions in resting metabolic rate, that drive the body to restore its previous weight. It is one of the most common concerns I encounter among patients who do engage with pharmacological treatment – worrying about weight regain once medication is stopped. That concern is not unfounded, but weight regain reflects the chronic nature of the condition, not treatment failure. Similar patterns are seen when treatment is withdrawn in other chronic diseases.

Even for patients who do engage with the healthcare system, access to meaningful support remains deeply uneven. Waiting times for specialist review can stretch to 18 months, and in primary care, limited consultation time makes it difficult to properly address the behavioural, psychological and metabolic dimensions of a condition as complex as obesity. Access to pharmacotherapy and specialist services is typically restricted to individuals meeting strict BMI and comorbidity thresholds. While these criteria prioritise patients at highest risk, they mean that only a relatively small proportion of people living with obesity are currently eligible for comprehensive treatment within the NHS.

The concern that expanding treatment is unaffordable at scale is understandable, but it needs to be weighed against the cost of the current approach. Obesity is already estimated to cost the NHS over £11.4bn every year, with wider societal costs reaching £74.3bn. Delayed intervention shifts those costs downstream into more complex and expensive conditions including type 2 diabetes and cardiovascular disease. Earlier, structured intervention has the potential to reduce that long-term burden, even if it requires upfront investment.

The emergence of GLP-1 receptor agonists represents one of the most significant advances in obesity medicine in recent decades. Medications such as semaglutide and tirzepatide target the biological pathways that regulate appetite and satiety, mimicking incretin hormones to influence signalling between the gut and the brain.

The STEP-1 trial, published in the New England Journal of Medicine, demonstrated average associated weight reductions of nearly 15% when combined with lifestyle support, outcomes that have genuinely redefined expectations in the field.

Concerns about the cost and scalability of these treatments are legitimate, but they are policy challenges rather than clinical arguments against their use. Pricing models, eligibility criteria and negotiated access agreements will determine scalability and, as with other therapeutic areas, costs are likely to evolve over time.

Pharmacotherapy is not a replacement for behavioural support, clinical oversight and sustained follow-up. GLP-1s are not a shortcut but a catalyst – addressing the underlying biology of appetite and weight regulation to give patients a more realistic foundation to engage with the broader lifestyle changes that support long-term metabolic health. Used as part of a comprehensive, clinically supervised programme, they make lifestyle intervention more achievable.

Formal recognition of obesity as a chronic disease would shift the foundation on which care is built – supporting earlier diagnosis, structured treatment pathways, sustained clinical monitoring and greater investment in the multidisciplinary services, including dietitians, psychologists and metabolic specialists, that effective obesity care requires. It would also provide a clearer framework for training healthcare professionals in obesity medicine, an area that has historically received limited attention in medical education. As NHS demand grows and more patients seek support through both public and private providers, recognition would help establish a shared framework ensuring that the expansion of access is built on consistent, evidence-based standards across both sectors.

For patients, it would mean entering a healthcare system that recognises their disease as one that requires structured, long-term management rather than repeated cycles of short-term intervention. The WHO made its position clear over twenty years ago. The European Parliament and many leading health bodies have followed. What is required now is for UK policy to do the same.